Glp-1 Receptor Agonists In Dementia
Patent No. EP4054620 (titled "Glp-1 Receptor Agonists In Dementia") was filed by Novo Nordisk on Nov 5, 2020. The application was issued on May 29, 2024.
Patent Summary
Semaglutide, a GLP-1 receptor agonist, offers a new therapeutic approach for preventing or slowing dementia progression. Administering semaglutide to individuals with metabolic syndrome or other conditions associated with increased dementia risk, such as diabetes, cardiovascular disease, or obesity, has been shown to reduce the risk of dementia in clinical trials. The treatment's mechanism of action involves modulating metabolic pathways to improve cognitive function and reduce inflammation, with potential benefits extending to other conditions like diabetes and cardiovascular disease.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4054620
- Application Number
- EP20803489A
- Filing Date
- Nov 5, 2020
- Status
- Granted And Under Opposition
- Apr 27, 2024
- Publication Date
- May 29, 2024
- External Links
- Slate, Register , Google Patents